LHK
HMSCATi004-A
General
Cell Line |
|
| hPSCreg name | HMSCATi004-A |
| Cite as: | HMSCATi004-A (RRID:CVCL_C1PW) |
| Alternative name(s) |
LHK
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi007-A (IPSC0008, TMEM175 Q65P heterozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi009-A (IPSC0012, TMEM175 M393T homozygous) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi013-A (IPSC0017, LRRK2 M1646T (heterozygous)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi015-A (IPSC0020, LRRK2 N551K-R1398H-K1423K (protective haplotype)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi016-A (IPSC0021, Parkin homozygous deletion between exon 3 and 4) Donor's gene variants: PRKN, PRKN Donor diseases: Parkinson Disease CBIGi009-B (TMEM175 M393T homozygous (CBIGi009), IPSC0033) Donor's gene variants: TMEM175, TMEM175 Donor diseases: Parkinson Disease CBIGi027-A (LRRK2 G2385R (CBIGi027), IPSC0037) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi002-A (2890 (GBA W378G, heterozygous), 2890, IPSC0001) Donor's gene variants: GBA, GBA, GBA Donor diseases: Parkinson Disease CBIGi005-A (IPSC0003, LRRK2 G2019S) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi010-A (SOD1 A4S, IPSC0014) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi011-A (SOD1 I114T, IPSC0015) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi014-A (VAPB A2V, IPSC0019) Donor's gene variants: VAPB, VAPB Donor diseases: Amyotrophic Lateral Sclerosis |
| Last update | 18th February 2025 |
| User feedback | |
Provider |
|
| Generator | Stem Cell Application and Translation Laboratory (HMSCAT) |
External Databases |
|
| BioSamples | SAMEA14088256 |
| Cellosaurus | CVCL_C1PW |
| Wikidata | Q114311629 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA14088269 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Medical Ethics Committee of Hebei Medical University |
| Approval number | NO.2020202 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
Other medium:
Base medium: ncTarget
Main protein source: Knock-out serum replacement Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|||||
| SSEA-4 |
Yes |
|
||||
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
| Marker | Expressed |
| actin alpha 2, smooth muscle |
Yes |
Morphology
M-2.tif
ACTA2 merged with DAPI
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.